If you’re a federal employee receiving GLP-1 coverage under FEHB, upcoming changes could make it more structured and potentially harder.
Where things stand today
Since 2025, FEHB plans have been directed to ensure access to GLP-1 medications for weight loss, along with additional oral options. That has put federal employees and retirees in a stronger position than many in the private sector, where coverage for these drugs has been far less consistent.
What’s changing for 2027
GLP-1 coverage is not going away. But starting in 2027, it comes with new conditions. The biggest change is that you will need to participate in a structured weight management program to get and keep coverage for an anti-obesity medication.
In practical terms, that means:
- Before starting treatment: You will need to show that you are actively participating in an intensive behavioral therapy (IBT) program
- While on the medication: You will need to continue that participation
- For approval: Carriers will use prior authorization to verify both
This formalizes something that was already happening in some plans, but raises the bar and makes it a more consistent expectation across FEHB carriers.
What this means in practice
For current users, coverage continues through 2026. After that, expect your plan to require documentation showing you are enrolled in and participating in a qualifying program.
If you are considering starting a GLP-1, the process will likely involve an extra step. You will need to join and engage in a structured weight management program before your prescription is approved.
Exactly how this is implemented will vary by carrier, which makes plan details more important than ever.
The cost angle
This shift is not just about clinical outcomes. It is also about cost. FEHB premiums increased 11.2% between 2024 and 2025, with specialty medications, including GLP-1s, contributing to that rise. Tying coverage to behavioral programs is one way to manage both utilization and long-term spending.
At the same time, out-of-pocket costs already vary widely. Some plans have increased cost-sharing for GLP-1s used for weight loss, so it is worth checking your plan’s formulary/preferred drug list rather than assuming your costs will stay the same.
A note for retirees
Retirees enrolled in FEHB plans that coordinate with Medicare, particularly Medicare Advantage Employer Group Waiver Plans (EGWPs), are still in a relatively strong position.
While traditional Medicare generally does not cover weight-loss medications, these FEHB-linked plans can offer enhanced coverage, helping preserve access to GLP-1s in retirement.
What to watch
OPM sets the baseline, but each carrier decides how to implement it. If GLP-1 coverage is important to you, do not assume your current access carries over. Review your plan’s formulary/preferred drug list and prior authorization requirements during Open Season. That is where the real differences will show up.
